Oklahoma Medical Cannabis Laws & Regulations

In April 2015, Gov. Fallin signed HB 2154, Katie and Cayman's Law. 

Katie and Cayman’s Law allows physicians in Oklahoma to recommend a clinical trial with cannabis oil containing high concentrations of CBD (one of the compounds founds in cannabis) to minors (18 years and under) suffering from a severe epilepsy disorder (e.g. Lennox-Gastaut Syndrome or Dravet Syndrome). The CBD oil for the trial must be obtained from a provider approved by the U.S. Food and Drug Administration (“FDA”) who has manufactured and tested the oil in a facility approved by the FDA. 

The law also exempts minors and their guardians or caretakers from criminal prosecution for possession of CBD oil if they have received a written certification from a physician licensed in Oklahoma that the person suffers from a severe form of epilepsy that is not adequately treated by traditional medical therapies.

In each case, the CBD oil may not contain more than 0.3% THC.

In May 2016, Gov. Fallin signed HB 2835, which expanded the law to apply to all persons (as opposed to just minors).  This bill also extended legal protection for possession of CBD oil to include patients suffering from spasticity due to multiple sclerosis or paraplegia, intractable nausea and vomiting or appetite stimulation with chronic wasting diseases.

Neither bill created a framework for the production, distribution or analysis of the CBD oil. Presumably patients are supposed to illegally bring CBD oil in from another state or to participate in clinical trials conducted at Oklahoma universities.  


HB 2154- Katie and Cayman's Law (2015)

HB 2835 (2016) - expansion of protections